CD11b Expression and Its Association with Clinical Biochemical Parameters in Patients with Acute Myeloid Leukemia

Objective:Acute myeloid leukemia (AML) is a hematological malignancy characterized by marked clinical and biological heterogeneity, resulting in variable prognosis. Immunophenotypic markers have gained increasing importance in predicting disease outcome and guiding clinical management. This study aimed to evaluate the prognostic significance of CD11b expression and its association with biochemical, hematological, and coagulation parameters in adult patients diagnosed with AML.Methods:This retrospective observational study included 50 adult patients aged between 18 and 75 years who were diagnosed with AML between 2019 and 2023. Demographic data, complete blood count, biochemical and coagulation parameters, and CD11b expression levels measured by flow cytometry at diagnosis were analyzed. In our study, our patients were grouped into two separate categories. The first grouping consisted of 5 subgroups, while the second grouping consisted of 2 subgroups. Statistical analyses were performed to assess the relationship between CD11b expression and laboratory parameters.Results:In our study revealed significant differences in WBC levels between group. One of the striking findings of our study is the relationship between CD11b expression levels and serum creatinine levels. There was a significant difference in prothrombin time (PT) was found between the groupsConclusion:CD11b expression may serve as an important prognostic immunophenotypic marker in patients with AML. Its significant association with biochemical and coagulation parameters suggests that CD11b could contribute to risk stratification and clinical decision-making processes in AML management.